Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

H-FABP as a Biomarker in Transient Ischemic Attack

  • Guamán-Pilco, Daisy R.
  • Chocano Navarro, Elvira
  • Palà, Elena
  • Lamana-Vallverdú, Marcel
  • Penalba, Anna
  • García-Rodríguez, Paula
  • Rubiera, Marta
  • Bustamante, Alejandro
  • Rovira, Alex
  • Pérez-Sánchez, Soledad
  • Azurmendi, Leire
  • Reymond, Sandrine
  • Sánchez, Jean-Charles
  • Montaner, Joan
Data access statement: Is not available to the general public., The study investigates the utility of heart fatty-acid binding protein (H-FABP) in distinguishing TIA from mimics. Data from 175 patients from the StrokeChip multicenter study was retrospectively analyzed. H-FABP level was measured using a rapid point-of-care test. Findings revealed that H-FABP levels were higher in individuals with TIA compared to mimics [3.10 ng/mL (IQR 2.13-4.78) vs. 1.70 ng/mL (IQR 1.23-2.38)] (p < 0.001). The diagnostic performance of H-FABP, assessed using the area under the curve operating characteristic curve (AUC) was 0. 83 (95% CI = 0.76-0.90) for the final model, indicating good discriminative ability. The PanelomiX determined that a combined cutoff of > 1.85 ng/ml for H-FABP, age > 42.5 years, and baseline NIHSS > 3.5 had a 100% of sensitivity and 23.30% of specificity. The study suggests that H-FABP has potential as a TIA diagnostic biomarker. The rapid application of POCT's for H-FABP measurement supports its potential use in emergency departments and primary care settings., The first study (StrokeChip) was supported by the research project IDI20130009. Development, design, and validation of a Laboratory-on-a-chip tool for the early diagnosis of stroke and its differentiation from analogous pathologies, of the Center for the Development of Industrial Technology (CDTI). The Neurovascular Research Laboratory of the Vall d'Hebron Research Institute participates in the Spanish stroke research network RICORS (RD16/0019/00021) and received funding from Instituto de Salud Carlos III (ISCIII) DTS14/00004, PI18/00804, co-financed by the European Regional Development Fund (FEDER), for stroke biomarker research. The funders had no role in the study design or conduction., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

A Panel of Blood Biomarkers for the Diagnosis of Transient Ischemic Attacks

  • Guamán-Pilco, Daisy R.
  • Palà, Elena
  • Lamana-Vallverdú, Marcel
  • Penalba, Anna
  • García-Rodríguez, Paula
  • Rubiera, Marta
  • Bustamante, Alejandro
  • Pérez-Sánchez, Soledad
  • Montaner, Joan
Accurate diagnosis of transient ischemic attacks (TIAs) is challenging. This study was aimed at analyzing blood biomarkers to distinguish TIAs from mimics. The levels of eight candidate biomarkers were measured in 234 patients with suspected TIA, 103 of whom had TIA and 131 of whom had mimics. We compared the groups, examined the effects of the biomarkers via logistic regression, compared models with likelihood ratio tests, assessed predictive accuracy with receiver operating characteristic analysis, and optimized cutoff values with the PanelomiX algorithm. ApoC-III, IL-6, and vWF were the most effective biomarkers in discriminating TIAs from mimics after adjustment for clinical variables. The area under the curve was 0.73 for ApoC-III; 0.74 for IL-6; 0.74 for vWF; and 0.72 for the clinical model. The likelihood ratio test indicated that these biomarkers showed better fit than the clinical model: Apo-CIII (P ≤ 0.031), IL-6 (P ≤ 0.030), and vWF (P ≤ 0.040). With the PanelomiX algorithm, a model incorporating biomarker thresholds (Apo-CIII >132.29 ng/mL, IL-6 >5.45 pg/mL, vWF <280.09%, NIHSS score >4.5, and age >41.5 years) achieved a sensitivity of 100% and a specificity of 28% in distinguishing TIAs from mimics. These findings suggest that combining blood biomarkers with clinical data might potentially enhance TIA diagnosis., The Neurovascular Research Laboratory of the Vall d’Hebron Research Institute, which participates in the Spanish stroke research network RICORS (RD16/0019/00021), received funding from Instituto de Salud Carlos III (ISCIII) DTS14/00004, PI18/00804, and was co-financed by the European Regional Development Fund (FEDER) for stroke biomarker research. The funders had no role in the study design or conduct. The StrokeChip study was supported by the research project IDI20130009 (Development, design, and validation of a Laboratory-on-a-chip tool for the early diagnosis of stroke and its differentiation from analogous pathologies) at the Center for the Development of Industrial Technology (CDTI)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Blood Biomarker Panels for the Early Prediction of Stroke‐Associated Complications

  • Faura Llorens, Julia
  • Bustamante Rangel, Alejandro
  • Reverté, Silvia
  • Garcia Berrocoso, Teresa
  • Millán Torné, Mònica
  • Castellanos, Mar
  • Ventura Ripoll, Oriol
  • Rubiera Del Fueyo, Marta Aurora
  • Montaner Villalonga, Joan
Biomarkers; Stroke; Stroke‐associated infection, Biomarcadors; Ictus; Infecció associada a un ictus, Biomarcadores; Ictus; Infección asociada a un ictus, Background Acute decompensated heart failure (ADHF) and respiratory tract infections (RTIs) are potentially life‐threatening complications in patients experiencing stroke during hospitalization. We aimed to test whether blood biomarker panels might predict these complications early after admission. Methods and Results Nine hundred thirty‐eight patients experiencing ischemic stroke were prospectively recruited in the Stroke‐Chip study. Post‐stroke complications during hospitalization were retrospectively evaluated. Blood samples were drawn within 6 hours after stroke onset, and 14 biomarkers were analyzed by immunoassays. Biomarker values were normalized using log‐transformation and Z score. PanelomiX algorithm was used to select panels with the best accuracy for predicting ADHF and RTI. Logistic regression models were constructed with the clinical variables and the biomarker panels. The additional predictive value of the panels compared with the clinical model alone was evaluated by receiver operating characteristic curves. An internal validation through a 10‐fold cross‐validation with 3 repeats was performed. ADHF and RTI occurred in 19 (2%) and 86 (9.1%) cases, respectively. Three‐biomarker panels were developed as predictors: vascular adhesion protein‐1 >5.67, NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) >4.98 and d‐dimer >5.38 (sensitivity, 89.5%; specificity, 71.7%) for ADHF; and interleukin‐6 >3.97, von Willebrand factor >3.67, and d‐dimer >4.58 (sensitivity, 82.6%; specificity, 59.8%) for RTI. Both panels independently predicted stroke complications (panel for ADHF: odds ratio [OR] [95% CI], 10.1 [3–52.2]; panel for RTI: OR, 3.73 [1.95–7.14]) after adjustment by clinical confounders. The addition of the panel to clinical predictors significantly improved areas under the curve of the receiver operating characteristic curves in both cases. Conclusions Blood biomarkers could be useful for the early prediction of ADHF and RTI. Future studies should assess the usefulness of these panels in front of patients experiencing stroke with respiratory symptoms such as dyspnea., This project received funding from Instituto de Salud Carlos III (ISCIII) [DTS14/00004, PI17/02130], co‐financed by the European Regional Development Fund (FEDER), and from Fundació La Marató de TV3 [201706] and the European Union's Horizon 2020 research and innovation program [754517]. Neurovascular Research Laboratory takes part into the Spanish stroke research network INVICTUS+ (RD16/0019/0021). The funders had no role in the study design and conduction.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Blood Biomarker Panels for the Early Prediction of Stroke-Associated Complications

  • Faura, Júlia|||0000-0002-8436-1377
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • Reverté, Silvia|||0000-0002-2052-9978
  • García-Berrocoso, Teresa|||0000-0001-7387-7389
  • Millán Torné, Mònica|||0000-0002-4692-5936
  • Castellanos, María del Mar|||0000-0003-3116-1352
  • Lara-Rodríguez, Blanca|||0009-0003-4534-9687
  • Zaragoza, Josep
  • Ventura, Oriol
  • Hernández-Pérez, María|||0000-0001-8279-7954
  • van Eendenburg, Cecile
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • López-Cancio, Elena|||0000-0001-5757-9074
  • Cánovas Verge, David|||0000-0002-3483-8106
  • Serena, Joaquín|||0000-0002-4478-7744
  • Rubiera Del Fueyo, Marta A.|||0000-0001-8100-9477
  • Dávalos, Antoni|||0000-0003-2949-5679
  • Montaner, Joan|||0000-0003-4845-2279
Acute decompensated heart failure (ADHF) and respiratory tract infections (RTIs) are potentially life-threatening complications in patients experiencing stroke during hospitalization. We aimed to test whether blood biomarker panels might predict these complications early after admission. Nine hundred thirty-eight patients experiencing ischemic stroke were prospectively recruited in the Stroke-Chip study. Post-stroke complications during hospitalization were retrospectively evaluated. Blood samples were drawn within 6 hours after stroke onset, and 14 biomarkers were analyzed by immunoassays. Biomarker values were normalized using log-transformation and Z score. PanelomiX algorithm was used to select panels with the best accuracy for predicting ADHF and RTI. Logistic regression models were constructed with the clinical variables and the biomarker panels. The additional predictive value of the panels compared with the clinical model alone was evaluated by receiver operating characteristic curves. An internal validation through a 10-fold cross-validation with 3 repeats was performed. ADHF and RTI occurred in 19 (2%) and 86 (9.1%) cases, respectively. Three-biomarker panels were developed as predictors: vascular adhesion protein-1.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Blood Biomarker Panels for the Early Prediction of Stroke‐Associated Complications

  • Faura Llorens, Julia
  • Bustamante Rangel, Alejandro
  • Reverté, Silvia
  • Garcia Berrocoso, Teresa
  • Millán Torné, Mònica
  • Castellanos, Mar
  • Ventura Ripoll, Oriol
  • Rubiera Del Fueyo, Marta Aurora
  • Montaner Villalonga, Joan
Biomarkers; Stroke; Stroke‐associated infection, Biomarcadors; Ictus; Infecció associada a un ictus, Biomarcadores; Ictus; Infección asociada a un ictus, Background Acute decompensated heart failure (ADHF) and respiratory tract infections (RTIs) are potentially life‐threatening complications in patients experiencing stroke during hospitalization. We aimed to test whether blood biomarker panels might predict these complications early after admission. Methods and Results Nine hundred thirty‐eight patients experiencing ischemic stroke were prospectively recruited in the Stroke‐Chip study. Post‐stroke complications during hospitalization were retrospectively evaluated. Blood samples were drawn within 6 hours after stroke onset, and 14 biomarkers were analyzed by immunoassays. Biomarker values were normalized using log‐transformation and Z score. PanelomiX algorithm was used to select panels with the best accuracy for predicting ADHF and RTI. Logistic regression models were constructed with the clinical variables and the biomarker panels. The additional predictive value of the panels compared with the clinical model alone was evaluated by receiver operating characteristic curves. An internal validation through a 10‐fold cross‐validation with 3 repeats was performed. ADHF and RTI occurred in 19 (2%) and 86 (9.1%) cases, respectively. Three‐biomarker panels were developed as predictors: vascular adhesion protein‐1 >5.67, NT‐proBNP (N‐terminal pro‐B‐type natriuretic peptide) >4.98 and d‐dimer >5.38 (sensitivity, 89.5%; specificity, 71.7%) for ADHF; and interleukin‐6 >3.97, von Willebrand factor >3.67, and d‐dimer >4.58 (sensitivity, 82.6%; specificity, 59.8%) for RTI. Both panels independently predicted stroke complications (panel for ADHF: odds ratio [OR] [95% CI], 10.1 [3–52.2]; panel for RTI: OR, 3.73 [1.95–7.14]) after adjustment by clinical confounders. The addition of the panel to clinical predictors significantly improved areas under the curve of the receiver operating characteristic curves in both cases. Conclusions Blood biomarkers could be useful for the early prediction of ADHF and RTI. Future studies should assess the usefulness of these panels in front of patients experiencing stroke with respiratory symptoms such as dyspnea., This project received funding from Instituto de Salud Carlos III (ISCIII) [DTS14/00004, PI17/02130], co‐financed by the European Regional Development Fund (FEDER), and from Fundació La Marató de TV3 [201706] and the European Union's Horizon 2020 research and innovation program [754517]. Neurovascular Research Laboratory takes part into the Spanish stroke research network INVICTUS+ (RD16/0019/0021). The funders had no role in the study design and conduction.